Christine D Berg

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. pmc Genetic polymorphisms of the GNRH1 and GNRHR genes and risk of breast cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3)
    Federico Canzian
    German Cancer Research Center DKFZ, Heidelberg, Germany
    BMC Cancer 9:257. 2009
  2. pmc A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer
    Claire S Zhu
    Division of Cancer Prevention, National Cancer Institute, National Institute of Health, Bethesda, MD 20892 7346, USA
    Cancer Prev Res (Phila) 4:375-83. 2011
  3. doi request reprint The Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial: the prostate cancer screening results in context
    Christine D Berg
    Early Detection Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, MD 20852, USA
    Acta Oncol 50:12-7. 2011
  4. pmc Breast cancer epidemiology according to recognized breast cancer risk factors in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial Cohort
    James V Lacey
    Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Rockville, MD, USA
    BMC Cancer 9:84. 2009
  5. pmc The chromosome 2p21 region harbors a complex genetic architecture for association with risk for renal cell carcinoma
    Summer S Han
    Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 7231, USA
    Hum Mol Genet 21:1190-200. 2012
  6. doi request reprint Applying the National Lung Screening Trial eligibility criteria to the US population: what percent of the population and of incident lung cancers would be covered?
    Paul F Pinsky
    Detection Branch, Division of Cancer Prevention, National Cancer Institute, 6130 Executive Blvd, EPN 3064, Bethesda, Maryland, 20892, USA
    J Med Screen 19:154-6. 2012
  7. pmc Targeting of low-dose CT screening according to the risk of lung-cancer death
    Stephanie A Kovalchik
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, and Information Management Services, Rockville, MD, USA
    N Engl J Med 369:245-54. 2013
  8. doi request reprint Potential effect of the risk of ovarian cancer algorithm (ROCA) on the mortality outcome of the Prostate, Lung, Colorectal and Ovarian (PLCO) trial
    Paul F Pinsky
    Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Int J Cancer 132:2127-33. 2013
  9. pmc Estrogen metabolism and risk of breast cancer in postmenopausal women
    Barbara J Fuhrman
    Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    J Natl Cancer Inst 104:326-39. 2012
  10. pmc Cumulative incidence of false-positive results in repeated, multimodal cancer screening
    Jennifer Miller Croswell
    Office of the Director, Office of Disease Prevention, National Institutes of Health, 6100 Executive Blvd, Suite 2B 03, Bethesda, MD 20892, USA
    Ann Fam Med 7:212-22. 2009

Detail Information

Publications29

  1. pmc Genetic polymorphisms of the GNRH1 and GNRHR genes and risk of breast cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3)
    Federico Canzian
    German Cancer Research Center DKFZ, Heidelberg, Germany
    BMC Cancer 9:257. 2009
    ..We studied the association between breast cancer risk and polymorphisms in genes that code for GNRH1 and its receptor (GNRHR) in the large National Cancer Institute Breast and Prostate Cancer Cohort Consortium (NCI-BPC3)...
  2. pmc A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer
    Claire S Zhu
    Division of Cancer Prevention, National Cancer Institute, National Institute of Health, Bethesda, MD 20892 7346, USA
    Cancer Prev Res (Phila) 4:375-83. 2011
    ..Thus, biomarker panels discovered in diagnostic samples may not validate in prediagnostic samples; utilizing prediagnostic samples for discovery may be helpful in developing validated early detection panels...
  3. doi request reprint The Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial: the prostate cancer screening results in context
    Christine D Berg
    Early Detection Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, MD 20852, USA
    Acta Oncol 50:12-7. 2011
    ..The Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO) was conducted in sites around USA during a period of marked secular changes in the use of prostate specific antigen (PSA) screening for prostate cancer...
  4. pmc Breast cancer epidemiology according to recognized breast cancer risk factors in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial Cohort
    James V Lacey
    Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Rockville, MD, USA
    BMC Cancer 9:84. 2009
    ..We therefore evaluated known risk factors for breast cancer in a cancer screening trial that does not have breast cancer as a study endpoint but is large enough to provide numerous analytic opportunities for breast cancer...
  5. pmc The chromosome 2p21 region harbors a complex genetic architecture for association with risk for renal cell carcinoma
    Summer S Han
    Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 7231, USA
    Hum Mol Genet 21:1190-200. 2012
    ..72 × 10(-9), per-allele OR = 1.28, 95% CI: 1.18-1.39) In conclusion, we report that chromosome 2p21 harbors a complex genetic architecture for common RCC risk variants...
  6. doi request reprint Applying the National Lung Screening Trial eligibility criteria to the US population: what percent of the population and of incident lung cancers would be covered?
    Paul F Pinsky
    Detection Branch, Division of Cancer Prevention, National Cancer Institute, 6130 Executive Blvd, EPN 3064, Bethesda, Maryland, 20892, USA
    J Med Screen 19:154-6. 2012
    ....
  7. pmc Targeting of low-dose CT screening according to the risk of lung-cancer death
    Stephanie A Kovalchik
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, and Information Management Services, Rockville, MD, USA
    N Engl J Med 369:245-54. 2013
    ..It is not known whether the benefits and potential harms of such screening vary according to lung-cancer risk...
  8. doi request reprint Potential effect of the risk of ovarian cancer algorithm (ROCA) on the mortality outcome of the Prostate, Lung, Colorectal and Ovarian (PLCO) trial
    Paul F Pinsky
    Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Int J Cancer 132:2127-33. 2013
    ..95 (95% CI: 0.74-1.23), respectively. Having utilized ROCA in PLCO would not have led to a significant mortality benefit of screening. However, ROCA could still show a significant effect in other screening trials, including UKCTOCS...
  9. pmc Estrogen metabolism and risk of breast cancer in postmenopausal women
    Barbara J Fuhrman
    Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    J Natl Cancer Inst 104:326-39. 2012
    ....
  10. pmc Cumulative incidence of false-positive results in repeated, multimodal cancer screening
    Jennifer Miller Croswell
    Office of the Director, Office of Disease Prevention, National Institutes of Health, 6100 Executive Blvd, Suite 2B 03, Bethesda, MD 20892, USA
    Ann Fam Med 7:212-22. 2009
    ..We sought to determine the cumulative risk of a false-positive screening result and the resulting risk of a diagnostic procedure for an individual participating in a multimodal cancer screening program...
  11. ncbi request reprint Ovarian cancer screening in women with a family history of breast or ovarian cancer
    James V Lacey
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20892, USA
    Obstet Gynecol 108:1176-84. 2006
    ..To evaluate positive predictive values of CA 125 or transvaginal ultrasonography screening for ovarian cancer according to family history of breast or ovarian cancer...
  12. pmc Performance of common genetic variants in breast-cancer risk models
    Sholom Wacholder
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Blvd, EPS 5050, MSC 7244, Bethesda, MD 20892, USA
    N Engl J Med 362:986-93. 2010
    ..Genomewide association studies have identified multiple genetic variants associated with breast cancer. The extent to which these variants add to existing risk-assessment models is unknown...
  13. pmc A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1)
    Gilles Thomas
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA
    Nat Genet 41:579-84. 2009
    ..1 (rs999737; P = 1.74 x 10(-7)) localizes to RAD51L1, a gene in the homologous recombination DNA repair pathway. We also confirmed associations with loci on chromosomes 2q35, 5p12, 5q11.2, 8q24, 10q26 and 16q12.1...
  14. doi request reprint Circulating insulin-like growth factor (IGF)-I and IGF binding protein (IGFBP)-3 levels and postmenopausal breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial (PLCO) cohort
    Catherine Schairer
    Epidemiology and Biostatistics Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, 20852 7244, USA
    Horm Cancer 1:100-11. 2010
    ..Further research should emphasize larger studies, including pooled analyses, analyses by cancer subtype, improved exposure assessment, and possible mechanisms...
  15. pmc Radiation-related cancer risks from CT colonography screening: a risk-benefit analysis
    Amy Berrington de Gonzalez
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Blvd, Bethesda, MD 20892, USA
    AJR Am J Roentgenol 196:816-23. 2011
    ..The purpose of this study was to estimate the ratio of cancers prevented to induced (benefit-risk ratio) for CT colonography (CTC) screening every 5 years from the age of 50 to 80 years...
  16. pmc Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries
    Amy Berrington de Gonzalez
    Radiation Epidemiology Branch, National Cancer Institute, Bethesda, MD 20892, USA
    Lancet Oncol 12:353-60. 2011
    ..We aimed to estimate the proportion of second cancers attributable to radiotherapy in adults with data from the US Surveillance, Epidemiology and End Results (SEER) cancer registries...
  17. pmc Pathologic findings following false-positive screening tests for ovarian cancer in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial
    Sarah J Nyante
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, 6120 Executive Blvd, Rockville, MD 20852, USA
    Gynecol Oncol 120:474-9. 2011
    ..We examined relationships between histopathologic diagnoses, false-positive test group, and participant and screening test characteristics...
  18. ncbi request reprint Workshop on imaging science development for cancer prevention and preemption
    Gary J Kelloff
    NIH NCI DCTD, Cancer Imaging Program, Bethesda, MD, USA
    Cancer Biomark 3:1-33. 2007
    ..Imaging devices, alone or in combination with anticancer drugs, may also provide novel interventions to treat or prevent precancer...
  19. pmc Genetic variation on 9p22 is associated with abnormal ovarian ultrasound results in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial
    Nicolas Wentzensen
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, United States of America
    PLoS ONE 6:e21731. 2011
    ..The single nucleotide polymorphism (SNP) markers localize to the BNC2 gene, which has been associated with ovarian development...
  20. pmc The National Lung Screening Trial's Endpoint Verification Process: determining the cause of death
    Pamela M Marcus
    Division of Cancer Prevention, National Cancer Institute, 6130 Executive Blvd, Bethesda, MD 20892 7354, USA
    Contemp Clin Trials 32:834-40. 2011
    ..We describe the National Lung Screening Trial's (NLST's) death review approach, the Endpoint Verification Process (EVP), which strives to minimize errors in assignment of cause of death due to lung cancer...
  21. pmc Lung cancer screening: promise and pitfalls
    Judith J Smith
    Lung and Upper Aerodigestive Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, NIH, US Department of Health and Human Services, Bethesda, MD 20892, USA
    Semin Oncol Nurs 24:9-15. 2008
    ..To provide an overview of the status of lung cancer screening...
  22. doi request reprint Serum levels of vitamin D metabolites and breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial
    D Michal Freedman
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Department of Health and Human Services, Bethesda, MD 20892 7238, USA
    Cancer Epidemiol Biomarkers Prev 17:889-94. 2008
    ....
  23. doi request reprint Prostate-specific antigen screening for prostate cancer in older men in the United States of America
    Amanda Black
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD 20852, USA
    Gerontology 58:331-6. 2012
    ..We discuss the current PSA screening recommendations and practices in the USA and the benefits and harms of screening older populations...
  24. doi request reprint Fine mapping of 14q24.1 breast cancer susceptibility locus
    Phoebe Lee
    Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Hum Genet 131:479-90. 2012
    ..Therefore, we conclude that rs999737 is an optimal tag SNP for common variants in the 14q24.1 region and thus narrow the candidate variants that should be investigated in follow-up laboratory evaluation...
  25. doi request reprint Thyroid cancer rates and 131I doses from Nevada atmospheric nuclear bomb tests: an update
    Ethel S Gilbert
    Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892 7238, USA
    Radiat Res 173:659-64. 2010
    ..Nevertheless, the study adds support for an increased risk of thyroid cancer due to fallout, although the data are inadequate to quantify it...
  26. pmc Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3
    Mark P Purdue
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department Health and Human Services, Bethesda, Maryland, USA
    Nat Genet 43:60-5. 2011
    ..31 for rs4765623, which maps to SCARB1, the scavenger receptor class B, member 1 gene (P = 2.6 × 10⁻⁸). Our study reports previously unidentified genomic regions associated with RCC risk that may lead to new etiological insights...
  27. pmc Low-dose lung computed tomography screening before age 55: estimates of the mortality reduction required to outweigh the radiation-induced cancer risk
    Amy Berrington de Gonzalez
    Division of Cancer Epidemiology and Biostatistics, National Cancer Institute, Bethesda, MD 20892, USA
    J Med Screen 15:153-8. 2008
    ..e. the efficacy) needed to outweigh these risks for never and current-smokers. The risk of radiation-induced breast cancer was also estimated for women...
  28. ncbi request reprint Ovarian volume: determinants and associations with cancer among postmenopausal women
    Mark E Sherman
    Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Boulevard, Rockville, MD 20892, USA
    Cancer Epidemiol Biomarkers Prev 15:1550-4. 2006
    ..Confirmation of these findings in future studies, including analyses of serum hormone levels and tissues, may provide insights into hormonal carcinogenesis among older women...
  29. ncbi request reprint Methods for etiologic and early marker investigations in the PLCO trial
    Richard B Hayes
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, EPS 8114, Bethesda, MD 20892, USA
    Mutat Res 592:147-54. 2005
    ..g., diet), biochemical, and genetic factors. Early detection studies focus on blood-based biologic markers of early disease. Clinical epidemiology is also an important component of the PLCO trial...